[Federal Register Volume 76, Number 201 (Tuesday, October 18, 2011)]
[Notices]
[Page 64343]
[FR Doc No: 2011-26847]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP12-2-000]

Williston Basin Interstate Pipeline Company; Notice of Request
Under Blanket Authorization

    Take notice that on October 3, 2011 Williston Basin Interstate
Pipeline Company (Williston Basin), 1250 West Century Avenue, Bismarck,
North Dakota 58503, filed in Docket No. CP12-2-000, a Prior Notice
request pursuant to Sections 157.205 and 157.208 of the Commission's
Regulations under the Natural Gas Act for authorization to abandon
certain natural gas transmission facilities located in Dawson County,
Montana. Specifically, Williston Basin proposes to abandon a 10.325
mile looped portion of its 12-inch diameter Cabin Creek to Williston
line. Williston Basin intends to pig, purge, cap at each end and
abandon the pipeline in-place and asserts that the abandonment of the
pipeline and facilities is necessary due to the poor condition of the
pipeline, all as more fully set forth in the application which is on
file with the Commission and open to public inspection. The filing may
also be viewed on the Web at http://www.ferc.gov using the ``eLibrary''
link. Enter the docket number excluding the last three digits in the
docket number field to access the document. For assistance, contact
FERC at<EMAIL_ADDRESS>or call toll-free,<PHONE_NUMBER> or
TTY,<PHONE_NUMBER>.
    Any questions regarding this Application should be directed to
Keith A. Tiggelar, Director of Regulatory Affairs, Williston Basin
Interstate Pipeline Company, 1250 West Century Avenue, Bismark, North
Dakota 58503, or call<PHONE_NUMBER> or by e-mail
<EMAIL_ADDRESS>    Any person may, within 60 days after the issuance of the instant
notice by the Commission, file pursuant to Rule 214 of the Commission's
Procedural Rules (18 CFR 385.214) a motion to intervene or notice of
intervention. Any person filing to intervene or the Commission's staff
may, pursuant to section 157.205 of the Commission's Regulations under
the NGA (18 CFR 157.205) file a protest to the request. If no protest
is filed within the time allowed therefore, the proposed activity shall
be deemed to be authorized effective the day after the time allowed for
protest. If a protest is filed and not withdrawn within 30 days after
the time allowed for filing a protest, the instant request shall be
treated as an application for authorization pursuant to section 7 of
the NGA.
    Persons who wish to comment only on the environmental review of
this project should submit an original and two copies of their comments
to the Secretary of the Commission. Environmental commenter's will be
placed on the Commission's environmental mailing list, will receive
copies of the environmental documents, and will be notified of meetings
associated with he Commission's environmental review process.
Environmental commenter's will not be required to serve copies of filed
documents on all other parties. However, the non-party commentary, will
not receive copies of all documents filed by other parties or issued by
the Commission (except for the mailing of environmental documents
issued by the Commission) and ill not have the right to seek court
review of the Commission's final order.
    The Commission strongly encourages electronic filings of comments,
protests, and interventions via the Internet in lieu of paper. See 18
CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web
site (http://www.ferc.gov) under the ``e-Filing'' link.

    Dated: October 11, 2011.
Kimberly D. Bose,
Secretary.
[FR Doc. 2011-26847 Filed 10-17-11; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 75, Number 240 (Wednesday, December 15, 2010)]
[Notices]
[Pages 78304-78306]
[FR Doc No: 2010-31482]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-63504; File No. SR-Phlx-2010-174]

Self-Regulatory Organizations; NASDAQ OMX PHLX LLC; Notice of
Filing and Immediate Effectiveness of Proposed Rule Change To Extend
the Pilot Period of the Trading Pause for Individual Stocks Contained
in the Standard & Poor's 500 Index, Russell 1000 Index, and Specified
Exchange Traded Products That Experience a Price Change of 10% or More
During a Five-Minute Period

December 9, 2010.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 \2\ thereunder, notice is hereby given
that on December 7, 2010, NASDAQ OMX PHLX LLC (``Phlx'' or
``Exchange'') filed with the Securities and Exchange Commission (the
``Commission'') the proposed rule change as described in Items I and II
below, which Items have been prepared by the Exchange. The Commission
is publishing this notice to solicit comments on the proposed rule
change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to extend the pilot period of the trading
pause for individual stocks contained in the Standard & Poor's 500
Index, Russell 1000 Index, and specified Exchange Traded Products that
experience a price change of 10% or more during a five-minute period,
so that the pilot will now expire on April 11, 2011.
    The text of the proposed rule change is below. Proposed new
language is in italics; proposed deletions are in brackets.
* * * * *
Rule 3100. Trading Halts on PSX
(a) Authority To Initiate Trading Halts or Pauses
    In circumstances in which the Exchange deems it necessary to
protect investors and the public interest, and pursuant to the
procedures set forth in paragraph (c):
    (1)-(3) No change.
    (4) If a primary listing market issues an individual stock trading
pause in any of the Circuit Breaker Securities, as defined herein, the
Exchange will pause trading in that security until trading has resumed
on the primary listing market. If, however, trading has not resumed on
the primary listing market and ten minutes have passed since the
individual stock trading pause message has been received from the
responsible single plan processor, the Exchange may resume trading in
such stock. The provisions of this paragraph (a)(4) shall be in effect
during a pilot set to end on April 11, 2011 [December 10, 2010]. During
the pilot, the term ``Circuit Breaker Securities'' shall mean the
securities included in the S&P 500 [supreg] Index and the Russell 1000
[supreg] Index, as well as a pilot list of Exchange Traded Products.
    (b)-(c) No change.
* * * * *

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    On June 10, 2010, the Commission granted accelerated approval, for
a pilot period to end December 10, 2010, of proposed rule changes
submitted by the of the BATS Exchange, Inc., NASDAQ OMX BX, Inc.,
Chicago Board Options Exchange, Incorporated, Chicago Stock Exchange,
Inc., EDGA Exchange, Inc., EDGX Exchange, Inc., International
Securities Exchange LLC, The NASDAQ Stock Market LLC, New York Stock

Exchange LLC, NYSE Amex LLC, NYSE Arca, Inc., and National Stock
Exchange, Inc. (collectively, the ``Exchanges''), to pause trading
during periods of extraordinary market volatility in S&P 500 stocks.\3\
The rules require the Listing Markets \4\ to issue five-minute trading
pauses for individual securities for which they are the primary Listing
Market if the transaction price of the security moves ten percent or
more from a price in the preceding five-minute period. The Listing
Markets are required to notify the other Exchanges and market
participants of the imposition of a trading pause by immediately
disseminating a special indicator over the consolidated tape. Under the
rules, once the Listing Market issues a trading pause, the other
Exchanges are required to pause trading in the security on their
markets. On September 10, 2010, the Commission approved the respective
rule filings of the Exchanges to expand application of the pilot to
securities comprising the Russell 1000[supreg] Index and specified
Exchange Traded Products.\5\
---------------------------------------------------------------------------

    \3\ Securities Exchange Act Release No. 62252 (June 10, 2010),
75 FR 34186 (June 16, 2010).
    \4\ The term ``Listing Markets'' refers collectively to NYSE,
NYSE Amex, NYSE Arca, and NASDAQ.
    \5\ Securities Exchange Act Release No. 62884 (September 10,
2010), 75 FR 56618 (September 16, 2010).
---------------------------------------------------------------------------

    In connection with its resumption of trading of NMS Stocks through
the NASDAQ OMX PSX system, the Exchange adopted Rule 3100(a)(4) so that
it could participate in the pilot program.\6\ On September 29, 2010,
the Exchange amended Rule 3100(a)(4) to include stocks comprising the
Russell 1000[supreg] Index and specified Exchange Traded Products.\7\
---------------------------------------------------------------------------

    \6\ Securities Exchange Act Release No. 62877 (September 9,
2010), 75 FR 56633 (September 16, 2010).
    \7\ Securities Exchange Act Release No. 63004 (September 29,
2010), 75 FR 61547 (October 5, 2010).
---------------------------------------------------------------------------

    The Exchange believes that the pilot program has been successful in
reducing the negative impacts of sudden, unanticipated price movements
in the securities covered by the pilot. The Exchange also believes that
an additional four month extension of the pilot is warranted so that it
may continue to assess whether additional securities need to be added
and whether the parameters of the rule need to be modified to
accommodate trading characteristics of different securities.
Accordingly, the Exchange is filing to seek a four-month extension of
the existing pilot.
2. Statutory Basis
    The statutory basis for the proposed rule change is Section 6(b)(5)
of the Securities Exchange Act of 1934 (the ``Act''),\8\ which requires
the rules of an exchange to promote just and equitable principles of
trade, to remove impediments to and perfect the mechanism of a free and
open market and a national market system and, in general, to protect
investors and the public interest. The proposed rule change also is
designed to support the principles of Section 11A(a)(1) \9\ of the Act
in that it seeks to assure fair competition among brokers and dealers
and among exchange markets. The Exchange believes that the proposed
rule meets these requirements in that it promotes transparency and
uniformity across markets concerning decisions to pause trading in a
security when there are significant price movements.
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 78f(b)(5).
    \9\ 15 U.S.C. 78k-1(a)(1).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
result in any burden on competition that is not necessary or
appropriate in furtherance of the purposes of the Act, as amended.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not: (1)
Significantly affect the protection of investors or the public
interest; (2) impose any significant burden on competition; and (3)
become operative for 30 days from the date on which it was filed, or
such shorter time as the Commission may designate if consistent with
the protection of investors and the public interest, it has become
effective pursuant to Section 19(b)(3)(A) of the Act \10\ and Rule 19b-
4(f)(6) thereunder.\11\
---------------------------------------------------------------------------

    \10\ 15 U.S.C. 78s(b)(3)(A).
    \11\ 17 CFR 240.19b-4(f)(6). When filing a proposed rule change
pursuant to Rule 19b-4(f)(6) under the Act, an exchange is required
to give the Commission written notice of its intent to file the
proposed rule change, along with a brief description and text of the
proposed rule change, at least five business days prior to the date
of filing of the proposed rule change, or such shorter time as
designated by the Commission. The Commission notes that the Exchange
has satisfied this requirement.
---------------------------------------------------------------------------

    A proposed rule change filed under Rule 19b-4(f)(6) normally may
not become operative prior to 30 days after the date of filing.\12\
However, Rule 19b-4(f)(6) \13\ permits the Commission to designate a
shorter time if such action is consistent with the protection of
investors and the public interest. The Exchange has requested that the
Commission waive the 30-day operative delay.
---------------------------------------------------------------------------

    \12\ 17 CFR 240.19b-4(f)(6)(iii).
    \13\ Id.
---------------------------------------------------------------------------

    The Commission has considered the Exchange's request to waive the
30-day operative delay. The Commission believes that waiving the 30-day
operative delay is consistent with the protection of investors and the
public interest, as it will allow the pilot program to continue
uninterrupted, thereby avoiding the investor confusion that could
result from a temporary interruption in the pilot program.\14\
Therefore, the Commission designates the proposed rule change to be
operative upon filing.
---------------------------------------------------------------------------

    \14\ For the purposes only of waiving the operative date of this
proposal, the Commission has considered the proposed rule's impact
on efficiency, competition, and capital formation. See 15 U.S.C.
78c(f).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act. If the Commission
takes such action, the Commission shall institute proceedings to
determine whether the proposed rule change should be approved or
disapproved. If the Commission takes such action, the Commission shall
institute proceedings to determine whether the proposed rule change
should be approved or disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-Phlx-2010-174 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-Phlx-2010-174. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for website viewing and
printing in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Copies of the filing also will be available for
inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-Phlx-2010-174 and should be
submitted on or before January 5, 2011.
---------------------------------------------------------------------------

    \15\ 17 CFR 200.30-3(a)(12).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\15\
Florence E. Harmon,
Deputy Secretary.
[FR Doc. 2010-31482 Filed 12-14-10; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 84, Number 189 (Monday, September 30, 2019)]
[Notices]
[Pages 51594-51595]
[FR Doc No: 2019-21002]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-D-3361]

Eligibility Criteria for Expanded Conditional Approval of New
Animal Drugs; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft guidance for industry (GFI) #261 entitled
``Eligibility Criteria for Expanded Conditional Approval of New Animal
Drugs.'' This draft guidance is intended for persons interested in
pursuing conditional approval of new animal drugs for certain major
uses in major species. Eligibility for conditional approval has been
expanded beyond minor uses in major species and minor species to
include certain major uses. The Center for Veterinary Medicine (CVM)
refers to the process for conditionally approving new animal drugs that
are not minor use and minor species (MUMS) drugs as ``expanded
conditional approval.'' The purpose of expanded conditional approval is
to incentivize development of new animal drugs for serious or life-
threatening conditions or unmet animal or human health needs under
circumstances where a demonstration of effectiveness would require a
complex or particularly difficult study or studies. This draft guidance
defines certain terms, clarifies the eligibility criteria for expanded
conditional approval, and describes the criteria CVM intends to
consider when determining expanded conditional approval eligibility.

DATES: Submit either electronic or written comments on the draft
guidance by January 28, 2020 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2019-D-3361 for ``Eligibility Criteria for Expanded Conditional
Approval of New Animal Drugs.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations .gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of the guidance to the
Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine,
Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855.
Send one self-addressed adhesive label to assist that office in
processing your requests. See the SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Christopher Loss, Center for
Veterinary Medicine (HFV-116), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of draft GFI #261 entitled
``Eligibility Criteria for Expanded Conditional Approval of New Animal
Drugs.'' In 2013, in conjunction with the reauthorization of FDA's
animal drug user fee program, FDA agreed to consider whether it would
be appropriate to expand the concept of conditional approval in section
571 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.
360ccc) to include new animal drug use in major species for diseases or
conditions that would not be eligible for conditional approval under
the MUMS provisions of the FD&C Act. Through a public process and
working in concert with stakeholders, CVM explored the feasibility of
expanding the eligibility for conditional approval. CVM concluded that
conditional approval may be appropriate for new animal drugs intended
for a serious or life-threatening disease or condition, or for drugs
intended to address an unmet animal or human health need under
circumstances where a demonstration of effectiveness would require a
particularly difficult effectiveness study or studies. The Animal Drug
User Fee Amendments of 2018 amended section 571 of the FD&C Act to
include provisions for expanded conditional approval and directed FDA
to establish guidance or regulations to clarify the eligibility
criteria for expanded conditional approval.
    In accordance with the recent amendments to the FD&C Act, this
draft guidance proposes definitions for the following terms that appear
in section 571 of the FD&C Act:
     ``serious or life-threatening disease or condition''
     ``unmet animal or human health need,'' and
     ``complex or particularly difficult study or studies.''

II. Significance of Guidance

    This level 1 draft guidance is being issued consistent with FDA's
good guidance practices regulation (21 CFR 10.115). The draft guidance,
when finalized, will represent the current thinking of FDA on
``Eligibility Criteria for Expanded Conditional Approval of New Animal
Drugs.'' It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.
This guidance is not subject to Executive Order 12866.

III. Paperwork Reduction Act of 1995

    This draft guidance refers to previously approved collections of
information found in FDA regulations for new animal drug applications
submitted under sections 512(b) (21 U.S.C. 360b(b)) and 571 of the FD&C
Act. These collections of information are subject to review by the
Office of Management and Budget (OMB) under the Paperwork Reduction Act
of 1995 (44 U.S.C. 3501-3520). The collections of information in 21 CFR
514.1, 514.4, 514.5, 514.6, 514.8, and 514.11 have been approved under
OMB control number 0910-0032.

IV. Electronic Access

    Persons with access to the internet may obtain the draft guidance
at either https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm or
https://www.regulations.gov.

    Dated: September 23, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-21002 Filed 9-26-19; 11:15 am]
BILLING CODE 4164-01-P


[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Page 60848]
[FR Doc No: 2018-25776]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OLEM-2050-0154; FRL-9986-22-OEI]

Information Collection Activities; Submission to OMB for Review
and Approval; Comment Request; Criteria for Classification of Solid
Waste Disposal Facilities and Practices

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Environmental Protection Agency (EPA) has submitted an
information collection request (ICR), Criteria for Classification of
Solid Waste Disposal Facilities and Practices (EPA ICR Number 1745.09,
OMB Control Number 2050-0154) to the Office of Management and Budget
(OMB) for review and approval in accordance with the Paperwork
Reduction Act. This is a proposed extension of the ICR, which is
currently approved through November 30, 2018. Public comments were
previously requested via the Federal Register (83 FR 38141) on August
03, 2018 during a 60-day comment period. This notice allows for an
additional 30 days for public comments. A fuller description of the ICR
is given below, including its estimated burden and cost to the public.
An agency may not conduct or sponsor and a person is not required to
respond to a collection of information unless it displays a currently
valid OMB control number.

DATES: Additional comments may be submitted on or before December 27,
2018.

ADDRESSES: Submit your comments, referencing Docket ID Number EPA-HQ-
OLEM-2018-0317, to (1) EPA online using www.regulations.gov (our
preferred method), by email to [email protected], or by mail to: EPA
Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200
Pennsylvania Ave. NW, Washington, DC 20460, and (2) OMB via email to
[email protected]. Address comments to OMB Desk Officer for
EPA.
    EPA's policy is that all comments received will be included in the
public docket without change including any personal information
provided, unless the comment includes profanity, threats, information
claimed to be Confidential Business Information (CBI) or other
information whose disclosure is restricted by statute.

FOR FURTHER INFORMATION CONTACT: Craig Dufficy, Materials Recovery and
Waste Management Division, Office of Resource Conservation and
Recovery, mailcode 5304P, Environmental Protection Agency, 1200
Pennsylvania Ave. NW, Washington, DC 20460; telephone number: 703-308-
9037; fax number:<PHONE_NUMBER>; email address: [email protected].

SUPPLEMENTARY INFORMATION: Supporting documents, which explain in
detail the information that the EPA will be collecting, are available
in the public docket for this ICR. The docket can be viewed online at
www.regulations.gov or in person at the EPA Docket Center, WJC West,
Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone
number for the Docket Center is<PHONE_NUMBER>. For additional
information about EPA's public docket, visit http://www.epa.gov/dockets.
    Abstract: 40 Part 257, Subpart B established specific standards and
reporting and recordkeeping requirements for owners and operators of
new, existing, and lateral expansions of existing non-municipal non-
hazardous waste disposal units that receive conditionally exempt small
quantity generator (CESQG) hazardous wastes. In order to effectively
implement and enforce 40 CFR part 257 Subpart B on a State level,
owners/operators of construction and demolition waste landfills that
receive CESQG hazardous wastes have to comply with the reporting and
recordkeeping requirements.
    Form numbers: None.
    Respondents/affected entities: Entities potentially affected by
this action are the private sector, as well as State, Local, or Tribal
Governments.
    Respondent's obligation to respond: Mandatory under Section 4010(c)
and 3001(d)(4) of the Resource Conservation and Recovery Act (RCRA) of
1976.
    Estimated number of respondents: 152.
    Frequency of response: On occasion.
    Total estimated burden: 11,219 hours (per year). Burden is defined
at 5 CFR 1320.03(b).
    Total estimated cost: $1,951,843 per year, includes $374,184
annualized labor and $1,577,659 annualized capital or operation &
maintenance costs.
    Changes in the estimates: There is no change of hours in the total
estimated respondent burden compared with the ICR currently approved by
OMB.

Courtney Kerwin,
Director, Regulatory Support Division.
[FR Doc. 2018-25776 Filed 11-26-18; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 77, Number 21 (Wednesday, February 1, 2012)]
[Notices]
[Page 5010]
[FR Doc No: 2012-2212]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2012-0057; FRL-9337-1]

Notice of Availability of Memorandum of Understanding Between
U.S. Environmental Protection Agency and Department of the Interior,
Bureau of Land Management

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces the availability of a Memorandum of
Understanding (MOU) between the Environmental Protection Agency and the
Department of Interior, Bureau of Land Management. The two agencies
will work together to support and facilitate reviewing pesticide
regulatory activities under the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA) relevant to risk assessments for the active
ingredient formulations--aminopyralid, fluroxpyr, and rimsulfuron,
proposed by the Bureau of Land Management, as well as to update risk
assessment of two other ingredients.

FOR FURTHER INFORMATION CONTACT: Mario Steadman, Information Technology
and Resources Management Division (7502P), Office of Pesticide
Programs, Environmental Protection Agency, 1200 Pennsylvania Ave. NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>: email
address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action applies to the public in general. As such, the Agency
has not attempted to describe all the specific entities that may be
affected by this action. If you have any questions regarding the
applicability of this action to a particular entity, consult the person
listed under FOR FURTHER INFORMATION CONTACT.

B. How can I get copies of this document and other related information?

    EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2011-0057. Publicly available
docket materials are available either in the electronic docket at
http://www.regulations.gov, or, if only available in hard copy, at the
Office of Pesticide Programs (OPP) Regulatory Public Docket in Rm. S-
4400, One Potomac Yard (South Bldg.), 2777 S. Crystal Dr., Arlington,
VA. The hours of operation of this Docket Facility are from 8:30 a.m.
to 4 p.m., Monday through Friday, excluding legal holidays. The Docket
Facility telephone number is<PHONE_NUMBER>.
    The complete text of the MOU can also be viewed in the electronic
docket at regulations.gov.

II. Brief Summary of Memorandum of Understanding

    Under the MOU the EPA and the BLM will work together to support and
facilitate reviewing pesticide regulatory activities under the FIFRA
relevant to work on some risk assessments for active ingredient
formulations proposed by the BLM. Currently, the BLM is proposing to
use three new active ingredients: aminopyralid, fluroxpyr, and
rimsulfuron. The BLM is conducting human health and ecological risk
assessments to evaluate the risks to humans, and fish and wildlife,
from the use of these new active ingredients. In addition, the BLM is
proposing to update risk assessments for 2, 4-D and clopyralid.

List of Subjects

    Environmental protection, Confidential Business Information,
Interagency Agreements, Pesticides and pests, Memorandum of
Understanding.

    Dated: January 25, 2012.
Michael Hardy,
Acting Director, Information Technology and Resources Management
Division, Office of Pesticide Programs.
[FR Doc. 2012-2212 Filed 1-31-12; 8:45 am]
BILLING CODE 6560-50-P